QUIGLEY TO BEGIN TESTING OF DRUG FOR DIABETES COMPLICATIONS

A A

Quigley will begin patient screening and enrollment for the first of two Phase II trials to determine the safety profile of its drug candidate QR-333.

In an earlier proof-of-concept study, completed in France, QR-333 improved 67 percent of the key symptoms associated with this complication of diabetes, suggesting efficacy, the company said in a statement.